ArriVent – Talk Bio

Actionable Insights Powered by AI

ArriVent Expands ADC Pipeline with Exclusive License for MRG007 from Lepu Biopharma

3 months ago talkbio0Tagged Antibody-Drug Conjugates, ArriVent, Biopharma, Lepu Biopharma, Malignant neoplasm of gastrointestinal tract, MRG007

ArriVent BioPharma, Lepu Biopharma, MRG007, Antibody Drug Conjugate (ADC), Gastrointestinal Cancers, Exclusive License Agreement

WCLC24 Highlights: ArriVent’s Drug Aims to Address Tagrisso’s Limitations; Boehringer and Bayer Share Data on HER2-Mutated Lung Cancer

8 months ago talkbio0Tagged ArriVent, Bayer, Boehringer, EGFR-mutated, HER2-mutated lung cancer, Malignant neoplasm of lung, Tagrisso, WCLC24

WCLC24, ArriVent, Tagrisso, Boehringer, Bayer, HER2-mutated lung cancer, Lung cancer treatment, EGFR-mutated lung cancer

ArriVent Expands ADC Portfolio with $615 Million Alphamab Acquisition

11 months ago talkbio0Tagged Acquisition (action), Alphamab, ArriVent, Biotechnology, financing characteristics, portfolio, therapeutic autologous dendritic cells

ArriVent, ADC portfolio, Alphamab, acquisition, biotech, biotechnology, financing